HK1200839A1 - Bispecific -cell activator antibody - Google Patents

Bispecific -cell activator antibody

Info

Publication number
HK1200839A1
HK1200839A1 HK15101099.1A HK15101099A HK1200839A1 HK 1200839 A1 HK1200839 A1 HK 1200839A1 HK 15101099 A HK15101099 A HK 15101099A HK 1200839 A1 HK1200839 A1 HK 1200839A1
Authority
HK
Hong Kong
Prior art keywords
bispecific
cell activator
activator antibody
antibody
cell
Prior art date
Application number
HK15101099.1A
Other languages
Chinese (zh)
Inventor
徐悠深
許壽山
張銘
張銘傳
阮大同
Original Assignee
Dev Center Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dev Center Biotechnology filed Critical Dev Center Biotechnology
Publication of HK1200839A1 publication Critical patent/HK1200839A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
HK15101099.1A 2011-12-22 2015-02-02 Bispecific -cell activator antibody HK1200839A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579450P 2011-12-22 2011-12-22
PCT/US2012/070432 WO2013096346A1 (en) 2011-12-22 2012-12-19 Bispecific t-cell activator antibody

Publications (1)

Publication Number Publication Date
HK1200839A1 true HK1200839A1 (en) 2015-08-14

Family

ID=48655207

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101099.1A HK1200839A1 (en) 2011-12-22 2015-02-02 Bispecific -cell activator antibody

Country Status (4)

Country Link
US (1) US8961971B2 (en)
CN (1) CN104144949B (en)
HK (1) HK1200839A1 (en)
WO (1) WO2013096346A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012362378B2 (en) * 2011-12-27 2016-06-23 Dcb-Usa Llc Light chain-bridged bispecific antibody
WO2016081601A1 (en) * 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Methods and compositions for cancer treating conditions relating to over expressions of epha2
CN113150165A (en) 2014-12-22 2021-07-23 西雅图免疫公司 Bispecific tetravalent antibodies and methods of making and using same
US20200017588A1 (en) * 2016-10-14 2020-01-16 Dana-Farber Cancer Institute, Inc. Modular tetravalent bispecific antibody platform
CA3118397A1 (en) * 2018-11-01 2020-05-07 Shandong Newtime Pharmaceutical Co., Ltd. Bispecific antibody targeting cd3 and bcma, and uses thereof
TW202116808A (en) * 2019-07-19 2021-05-01 大陸商上海藥明生物技術有限公司 Polypeptide complex for conjugation and use thereof
EP4103583A1 (en) 2020-02-14 2022-12-21 Chang Gung Memorial Hospital Tandem repeat cancer-targeting peptides for molecular conjugation or engineering and uses thereof in cancer theranostics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020091170A (en) * 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
ES2528794T3 (en) * 2000-04-11 2015-02-12 Genentech, Inc. Multivalent antibodies and uses thereof
US7910101B2 (en) * 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
JP5290177B2 (en) * 2006-08-31 2013-09-18 セントカー・インコーポレーテツド GLP-2 mimetibodies, polypeptides, compositions, methods and uses
WO2008131242A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
NZ581395A (en) * 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
BRPI0817108B8 (en) * 2007-09-21 2021-05-25 Univ California composition comprising a fusion protein, kit comprising said composition and use thereof.
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
AU2012362378B2 (en) * 2011-12-27 2016-06-23 Dcb-Usa Llc Light chain-bridged bispecific antibody

Also Published As

Publication number Publication date
US20130165629A1 (en) 2013-06-27
US8961971B2 (en) 2015-02-24
WO2013096346A1 (en) 2013-06-27
CN104144949B (en) 2016-08-31
CN104144949A (en) 2014-11-12

Similar Documents

Publication Publication Date Title
HUS2100034I1 (en) Anti-angptl3 antibodies and uses thereof
IL281250A (en) Anti-phf-tau antibodies and their uses
HRP20180640T1 (en) Anti-b7-h3 antibody
IL272831A (en) Meditopes and meditope-binding antibodies and uses thereof
IL259826A (en) Anti-alphabetatcr antibody
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
IL232399A0 (en) Anti-fgfr2 antibodies and uses thereof
EP2756094A4 (en) Anti-b7-h4 antibodies and their uses
HK1199842A1 (en) Anti-siglec-15 antibodies and uses thereof -15
HK1200839A1 (en) Bispecific -cell activator antibody
TWI563004B (en) Anti-hxcr1 antibody
EP2769988A4 (en) Anti-gap43 antibody
EP2714074A4 (en) Anti-emr1 antibodies
GB201116342D0 (en) Antigen combinations